JP2024045183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024045183A5 JP2024045183A5 JP2024000732A JP2024000732A JP2024045183A5 JP 2024045183 A5 JP2024045183 A5 JP 2024045183A5 JP 2024000732 A JP2024000732 A JP 2024000732A JP 2024000732 A JP2024000732 A JP 2024000732A JP 2024045183 A5 JP2024045183 A5 JP 2024045183A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- composition
- liposomes
- therapeutic
- lyophilization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 36
- 239000002502 liposome Substances 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 20
- 238000004108 freeze drying Methods 0.000 claims 14
- 229940039227 diagnostic agent Drugs 0.000 claims 11
- 239000000032 diagnostic agent Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 10
- 239000002577 cryoprotective agent Substances 0.000 claims 6
- 235000012000 cholesterol Nutrition 0.000 claims 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- 230000000717 retained effect Effects 0.000 claims 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 229960000684 cytarabine Drugs 0.000 claims 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 3
- 229960000975 daunorubicin Drugs 0.000 claims 3
- 150000002016 disaccharides Chemical class 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 239000000155 melt Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000005192 partition Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550047P | 2011-10-21 | 2011-10-21 | |
| US61/550,047 | 2011-10-21 | ||
| JP2019172314A JP2020007367A (ja) | 2011-10-21 | 2019-09-20 | 凍結乾燥リポソーム |
| JP2021196626A JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196626A Division JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024045183A JP2024045183A (ja) | 2024-04-02 |
| JP2024045183A5 true JP2024045183A5 (enExample) | 2024-05-10 |
Family
ID=48141268
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537142A Active JP6133308B2 (ja) | 2011-10-21 | 2012-10-15 | 凍結乾燥リポソーム |
| JP2017074348A Active JP6359717B2 (ja) | 2011-10-21 | 2017-04-04 | 凍結乾燥リポソーム |
| JP2018095127A Active JP6592556B2 (ja) | 2011-10-21 | 2018-05-17 | 凍結乾燥リポソーム |
| JP2019172314A Pending JP2020007367A (ja) | 2011-10-21 | 2019-09-20 | 凍結乾燥リポソーム |
| JP2021196626A Active JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
| JP2024000732A Pending JP2024045183A (ja) | 2011-10-21 | 2024-01-05 | 凍結乾燥リポソーム |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537142A Active JP6133308B2 (ja) | 2011-10-21 | 2012-10-15 | 凍結乾燥リポソーム |
| JP2017074348A Active JP6359717B2 (ja) | 2011-10-21 | 2017-04-04 | 凍結乾燥リポソーム |
| JP2018095127A Active JP6592556B2 (ja) | 2011-10-21 | 2018-05-17 | 凍結乾燥リポソーム |
| JP2019172314A Pending JP2020007367A (ja) | 2011-10-21 | 2019-09-20 | 凍結乾燥リポソーム |
| JP2021196626A Active JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10028912B2 (enExample) |
| EP (2) | EP2768484B1 (enExample) |
| JP (6) | JP6133308B2 (enExample) |
| KR (5) | KR102024836B1 (enExample) |
| CN (2) | CN104114156A (enExample) |
| AU (1) | AU2012326370C9 (enExample) |
| BR (1) | BR112014009305B1 (enExample) |
| CA (1) | CA2852777C (enExample) |
| DK (1) | DK2768484T3 (enExample) |
| ES (1) | ES2750368T3 (enExample) |
| FR (1) | FR19C1063I2 (enExample) |
| HR (1) | HRP20191683T1 (enExample) |
| HU (2) | HUE045978T2 (enExample) |
| IL (1) | IL232161B (enExample) |
| LU (1) | LUC00135I2 (enExample) |
| NL (1) | NL301016I2 (enExample) |
| NO (1) | NO2019041I1 (enExample) |
| PL (1) | PL2768484T3 (enExample) |
| PT (1) | PT2768484T (enExample) |
| RU (1) | RU2648753C2 (enExample) |
| SI (1) | SI2768484T1 (enExample) |
| WO (1) | WO2013059133A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191683T1 (hr) * | 2011-10-21 | 2019-12-13 | Jazz Pharmaceuticals Res Llc | Liofilizirani liposomi |
| US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| CA2958769A1 (en) | 2014-08-28 | 2016-03-03 | The General Hospital Corporation | Compositions and methods for treatment of neurological disorders |
| US11298318B2 (en) * | 2015-04-13 | 2022-04-12 | Fountain Technologies International, Llc | One-step method for production of ultra-small lipid structures |
| CN113679689B (zh) | 2015-07-22 | 2023-09-01 | 日东电工株式会社 | 用于纳米粒冷冻干燥物形式的组合物及方法 |
| IL292080B2 (en) | 2015-11-11 | 2024-09-01 | Celator Pharmaceuticals Inc | Treatment regimens for hematologic cancers and methods of use thereof |
| SG10201913504XA (en) | 2016-02-26 | 2020-03-30 | Massachusetts Gen Hospital | Medical ice slurry production and delivery systems and methods |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CA3069019A1 (en) * | 2017-07-10 | 2019-01-17 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof |
| WO2020068979A1 (en) | 2018-09-25 | 2020-04-02 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| EP3990041B1 (en) * | 2019-06-28 | 2025-08-06 | Board of Regents, The University of Texas System | Method of reconstituting liposomal annamycin |
| EP4003295A1 (en) * | 2019-07-24 | 2022-06-01 | The General Hospital Corporation | Methods of creating a substance with different freezing points by encapsulation |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| CN115252563B (zh) * | 2022-06-24 | 2024-07-12 | 石药集团中奇制药技术（石家庄）有限公司 | 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法 |
| CN116003493B (zh) * | 2022-12-16 | 2025-02-28 | 常州金远药业制造有限公司 | 一种二价铜离子及阿糖胞苷的回收方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| JPS62501631A (ja) * | 1985-01-11 | 1987-07-02 | ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア | リポソ−ムの保持法 |
| CA1256372A (en) | 1985-04-11 | 1989-06-27 | Koichiro Miyazima | Process for producing liposome composition |
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4915951A (en) | 1987-12-03 | 1990-04-10 | California Institute Of Technology | Cryoprotective reagent |
| DE68916439T2 (de) * | 1988-10-05 | 1994-10-20 | Vestar Inc | Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens. |
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| IL125800A0 (en) * | 1996-02-19 | 1999-04-11 | Nycomed Imaging As | Thermally stabilized contrast agent |
| IT1289938B1 (it) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| NZ516648A (en) | 1999-07-16 | 2004-01-30 | Alza Corp | A liposome composition having resistance to freeze/thaw damage |
| US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| AU2002331481B2 (en) | 2001-10-03 | 2008-04-24 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| EP1443900B1 (en) * | 2001-11-13 | 2012-05-23 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| EP1448165B1 (en) | 2001-11-13 | 2007-09-19 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions and methods for improved drug retention |
| AU2003287526A1 (en) | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
| US20060240090A1 (en) * | 2003-04-02 | 2006-10-26 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| AU2005235455B2 (en) * | 2004-04-22 | 2011-01-20 | Jazz Pharmaceuticals Therapeutics, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| US7893338B2 (en) | 2004-07-15 | 2011-02-22 | Creative Technology Ltd | Method of composing music on a handheld device |
| US20060110441A1 (en) * | 2004-10-28 | 2006-05-25 | Harry Wong | Lyophilized liposome formulations and method |
| AU2005304914B2 (en) * | 2004-11-05 | 2012-02-16 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| US20080107722A1 (en) | 2004-11-18 | 2008-05-08 | Paul Tardi | Method For Loading Multiple Agents Into Delivery Vehicles |
| EP1951239A2 (en) | 2005-10-25 | 2008-08-06 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| ES2909903T3 (es) | 2007-02-16 | 2022-05-10 | Rotalec Ip Holdings Llc | Proporciones fijas de medicamentos para el tratamiento de cáncer hematopoyético y trastornos proliferativos |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| KR101563658B1 (ko) | 2007-11-28 | 2015-10-27 | 셀라토 파마슈티칼즈, 인코포레이티드 | 개선된 탁산 전달 시스템 |
| EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| ES2547698T3 (es) | 2009-12-03 | 2015-10-08 | Jiangsu Hengrui Medicine Co., Ltd. | Liposoma de irinotecán o su clorhidrato y método de preparación del mismo |
| EP2531175A2 (en) | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
| HRP20191683T1 (hr) * | 2011-10-21 | 2019-12-13 | Jazz Pharmaceuticals Res Llc | Liofilizirani liposomi |
-
2012
- 2012-10-15 HR HRP20191683 patent/HRP20191683T1/hr unknown
- 2012-10-15 JP JP2014537142A patent/JP6133308B2/ja active Active
- 2012-10-15 HU HUE12841616A patent/HUE045978T2/hu unknown
- 2012-10-15 KR KR1020147012039A patent/KR102024836B1/ko active Active
- 2012-10-15 PL PL12841616T patent/PL2768484T3/pl unknown
- 2012-10-15 EP EP12841616.1A patent/EP2768484B1/en not_active Revoked
- 2012-10-15 RU RU2014120475A patent/RU2648753C2/ru active
- 2012-10-15 CN CN201280059606.1A patent/CN104114156A/zh active Pending
- 2012-10-15 KR KR1020197027220A patent/KR102113753B1/ko active Active
- 2012-10-15 KR KR1020227034406A patent/KR20220141906A/ko not_active Ceased
- 2012-10-15 CN CN201810733439.3A patent/CN108853031A/zh active Pending
- 2012-10-15 CA CA2852777A patent/CA2852777C/en active Active
- 2012-10-15 BR BR112014009305-9A patent/BR112014009305B1/pt active IP Right Grant
- 2012-10-15 ES ES12841616T patent/ES2750368T3/es active Active
- 2012-10-15 PT PT128416161T patent/PT2768484T/pt unknown
- 2012-10-15 KR KR1020217023773A patent/KR102452305B1/ko active Active
- 2012-10-15 US US14/352,662 patent/US10028912B2/en active Active
- 2012-10-15 AU AU2012326370A patent/AU2012326370C9/en active Active
- 2012-10-15 KR KR1020207013990A patent/KR102284689B1/ko active Active
- 2012-10-15 WO PCT/US2012/060293 patent/WO2013059133A1/en not_active Ceased
- 2012-10-15 EP EP19183846.5A patent/EP3572071A1/en active Pending
- 2012-10-15 DK DK12841616.1T patent/DK2768484T3/da active
- 2012-10-15 SI SI201231668T patent/SI2768484T1/sl unknown
-
2014
- 2014-04-22 IL IL232161A patent/IL232161B/en active IP Right Grant
-
2017
- 2017-04-04 JP JP2017074348A patent/JP6359717B2/ja active Active
-
2018
- 2018-02-07 US US15/891,170 patent/US10166184B2/en active Active
- 2018-05-17 JP JP2018095127A patent/JP6592556B2/ja active Active
- 2018-11-05 US US16/181,203 patent/US10835492B2/en active Active
-
2019
- 2019-09-20 JP JP2019172314A patent/JP2020007367A/ja active Pending
- 2019-10-10 HU HUS1900047 patent/HUS1900047I1/hu unknown
- 2019-10-23 FR FR19C1063C patent/FR19C1063I2/fr active Active
- 2019-10-24 LU LU00135C patent/LUC00135I2/fr unknown
- 2019-10-25 NL NL301016C patent/NL301016I2/nl unknown
- 2019-11-25 NO NO2019041C patent/NO2019041I1/no unknown
-
2020
- 2020-11-13 US US17/097,530 patent/US20210169803A1/en not_active Abandoned
-
2021
- 2021-12-03 JP JP2021196626A patent/JP7476161B2/ja active Active
-
2022
- 2022-07-13 US US17/812,414 patent/US20230172855A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000732A patent/JP2024045183A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024045183A5 (enExample) | ||
| JP2020007367A5 (enExample) | ||
| JP7476161B2 (ja) | 凍結乾燥リポソーム | |
| JP2014532623A5 (enExample) | ||
| JP6216721B2 (ja) | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 | |
| JP3501289B2 (ja) | 医薬処方 | |
| US9005655B2 (en) | Non-pegylated long-circulating liposomes | |
| JPH01502270A (ja) | アンホテリシンｂ／硫酸コレステロール組成物およびその製造方法 | |
| WO2004017940A2 (en) | Pharmaceutically active lipid based formulation of sn38 | |
| CN102271659A (zh) | 伊立替康或盐酸伊立替康脂质体及其制备方法 | |
| JP2007522085A (ja) | 安定化されたトポテカンリポソーム組成物および方法 | |
| HU197988B (en) | Process for producing lyophilized pharmaceutical product containing anthracycline - glycoside - derivative | |
| JP2025118720A5 (enExample) | ||
| HUT77975A (hu) | Vízben oldhatatlan kamptotecinek lipid-komplexének liofilizátuma | |
| CN112137958A (zh) | 一种含阿霉素与免疫佐剂组合药物脂质体及其制备方法 | |
| JPS6248629A (ja) | アントラサイクリングリコシド溶液 | |
| CN103989624B (zh) | 一种盐酸伊立替康组合物及其制备方法 | |
| CN102188439A (zh) | 一种程序性释放多种药物的纳米粒脂质体及其制备与应用 | |
| CN101744767A (zh) | 包含喜树碱类抗肿瘤药物的热敏脂质体制剂 | |
| CA2135265A1 (en) | Stable lyophilized thiotepa composition | |
| US20200368170A1 (en) | A lipid nanoparticle composition and a pharmaceutical composition for treating a hematoproliferative disorder | |
| HU210834B (en) | Method for the preparation pharmaceutical composition for the treatment of dermatitis | |
| CN116459224A (zh) | 一种丁苯酞纳米脂质体冻干粉针剂及其制备方法 | |
| WO1993023015A1 (en) | Liposomal aminoglycoside compositions and process for their preparation | |
| JP2020521004A (ja) | ｃ（ＲＧＤ−ＡＣＰ−Ｋ）修飾血中滞留型リポソーム |